Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjogren's disease study

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels [...]